S.H. Park
About
S.H. Park is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, S.H. Park has authored 20 papers receiving a total of 128 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Surgery, 13 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S.H. Park's work include Bladder and Urothelial Cancer Treatments (12 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Urinary and Genital Oncology Studies (6 papers). S.H. Park is often cited by papers focused on Bladder and Urothelial Cancer Treatments (12 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Urinary and Genital Oncology Studies (6 papers). S.H. Park collaborates with scholars based in South Korea, United States and Japan. S.H. Park's co-authors include Matt D. Galsky, Aristotelis Bamias, Yohann Loriot, Fabio A.B. Schutz, Maria De Santis, Marina Mencinger, Sanjeev Mariathasan, Arash Rezazadeh Kalebasty, Eiji Kikuchi and B. Yа. Alekseev and has published in prestigious journals such as Annals of Oncology and Clinical Oncology.
In The Last Decade
S.H. Park
19 papers receiving 127 citations
Peers
S.H. Park
Sarbajit Mukherjee United States
З. З. Мамедли Russia
Gian Marco Palini Italy
Ariel Ann Nelson United States
Rosa Angela Filiberti Italy
G. Sen United Kingdom
Vladimir Kostorov Russia
William Carlos Nahas Brazil
O. Fernández-Calvo Spain
Sandra Brosda Australia
Citations per year, relative to S.H. Park S.H. Park (= 1×)
peers
Sarbajit Mukherjee
Countries citing papers authored by S.H. Park
Since
Specialization
Citations
This map shows the geographic impact of S.H. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.H. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.H. Park more than expected).
Fields of papers citing papers by S.H. Park
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by S.H. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.H. Park. The network helps show where S.H. Park may publish in the future.
Co-authorship network of co-authors of S.H. Park
This figure shows the co-authorship network connecting the top 25 collaborators of S.H. Park. A scholar is included among the top collaborators of S.H. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.H. Park. S.H. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Park, S.H., Éric Voog, Wim Demey, et al.. (2024). 1975P Avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC): Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 years in JAVELIN Bladder 100. Annals of Oncology. 35. S1144–S1144.
2.
Siefker‐Radtke, Arlene O., Nobuaki Matsubara, S.H. Park, et al.. (2023). 2359O Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt). Annals of Oncology. 34. S1199–S1199.
3.
Shin, Su‐Jin, S.H. Park, Vagif Atduev, et al.. (2022). 1752P Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011. Annals of Oncology. 33. S1339–S1339.
4.
Porta, Camillo, Robert J. Motzer, Tomáš Büchler, et al.. (2022). 1449MO Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study. Annals of Oncology. 33. S1205–S1206.
5.
Jo, Hyunji, Hong-Sik Kim, Jung Yong Hong, et al.. (2022). A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. Clinical Oncology. 34(8). e323–e328.
6.
Choueiri, Toni K., Piotr Tomczak, S.H. Park, et al.. (2021). 653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564. Annals of Oncology. 32. S679–S680.
7.
Powles, Thomas, Michiel S. van der Heijden, D. Castellano Gauna, et al.. (2020). 697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE). Annals of Oncology. 31. S550–S551.
8.
Powles, Thomas, Evgeny Kopyltsov, Francis Parnis, et al.. (2020). 745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC). Annals of Oncology. 31. S578–S579.
9.
Bamias, Aristotelis, Maria De Santis, José Ángel Arranz, et al.. (2020). 698O Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Annals of Oncology. 31. S551–S552.
10.
Grivas, Petros, S.H. Park, Éric Voog, et al.. (2020). 704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100. Annals of Oncology. 31. S555–S556.
11.
Grande, Enrique, Matt D. Galsky, Maria De Santis, et al.. (2019). IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC). Annals of Oncology. 30. v888–v889.
12.
Liu, Jin, Qing Zou, H. Li, et al.. (2019). First report of efficacy and safety from a phase II trial of tislelizumab, an anti-PD-1 antibody, for the treatment of PD-L1+ locally advanced or metastatic urothelial carcinoma (UC) in Asian patients. Annals of Oncology. 30. v367–v367.
13.
McDermott, David F., Ulka N. Vaishampayan, Marc Matrana, et al.. (2019). Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment. Annals of Oncology. 30. v482–v483.
14.
Loriot, Yohann, Andrea Necchi, S.H. Park, et al.. (2018). Erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study. Annals of Oncology. 29. viii327–viii328.
15.
Bang, Y-J., Narikazu Boku, Kyung-Woo Lee, et al.. (2016). gastrointestinal tumours, non-colorectal Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study. Annals of Oncology. 27. vi562–vi562.
16.
Park, S.H., Daniel Castellano, Daniel P. Petrylak, et al.. (2016). 285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC). Annals of Oncology. 27(suppl_9).
17.
Yoo, Keon Hee, S.H. Park, S.T. Kim, et al.. (2015). P-104 Multi-center phase III trial of Adjuvant Chemoradiotherapy in Stomach Tumors 2 (ARTIST 2). Annals of Oncology. 26. iv29–iv29.
18.
Sun, Yinghao, Hongcheng Shi, Chi‐Hau Chen, et al.. (2015). 243PD Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets). Annals of Oncology. 26. ix71–ix71.
19.
Jung, Ki Sun, H.S. Kim, Jin Yong Lee, et al.. (2014). Phase Ii Study of a Combination Chemotherapy with Weekly Docetaxel and Gemcitabine in Previously Treated Metastatic Esophageal Squamous Cell Cancer. Annals of Oncology. 25. iv231–iv231.
20.
Park, Joon Oh, Hong-Sik Kim, Su Jin Lee, et al.. (2014). Tumour Shrinkage at 6 Weeks Predicts Favorable Clinical Outcomes in a Phase III Study of Gemcitabine and Oxaliplatin with or Without Erlotinib for Advanced Biliary Tract Cancer. Annals of Oncology. 25. iv243–iv243.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sarbajit Mukherjee Breakdown of academic impact, for papers by З. З. Мамедли Breakdown of academic impact, for papers by Gian Marco Palini Breakdown of academic impact, for papers by Ariel Ann Nelson Breakdown of academic impact, for papers by Rosa Angela Filiberti Breakdown of academic impact, for papers by G. Sen Breakdown of academic impact, for papers by Vladimir Kostorov Breakdown of academic impact, for papers by William Carlos Nahas Breakdown of academic impact, for papers by O. Fernández-Calvo Breakdown of academic impact, for papers by Sandra Brosda